NCT06492941 - A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

142

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

April 14, 2026

Study Completion Date

November 21, 2026

Conditions

Advanced Pancreatic Cancer

Interventions

DRUG

Docetaxel for Injection (Albumin bound)

Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.

DRUG

Placebo

Placebo was human blood albumin without the active ingredient docetaxel

DRUG

Best supportive care

Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY